Rabbit anti-Human MEF2D Polyclonal Antibody | anti-MEF2D antibody

Anti-MEF2D Antibody, Rabbit Polyclonal

Cat. Num. AAA256369

• Reactivity: Human
• Applications: Immunoprecipitation, Immunofluorescence, Immunocytochemistry, Immunohistochemistry, Western Blot
• Purity: Protein A & Antigen Affinity
• Synonyms: MEF2D, Antibody; Anti-MEF2D Antibody, Rabbit Polyclonal; MEF2D Antibody, Rabbit PAb, Antigen Affinity Purified; myocyte enhancer factor 2D; anti-MEF2D antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: Rabbit IgG
• Specificity: Human MEF2D
• Purity/Purification: Protein A & Antigen Affinity
• Form/Format: Liquid; PBS, pH7.0 with 0.03% Proclin300

• Applicable Applications for anti-MEF2D antibody: IP (Immunoprecipitation), IF (Immunofluorescence), ICC (Immunocytochemistry), IHC (Immunohistochemistry), WB (Western Blot)
• Immunogen: E Coli-derived Human MEF2D fragment
• Conjugation: Unconjugated
• Preparation: Produced in rabbits immunized with E Coli-derived Human MEF2D fragment, and purified by antigen affinity chromatography.
• Preparation and Storage: This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Avoid repeated freeze-thaw cycles.

IP (Immunoprecipitation)

(MEF2D was immunoprecipitated using:Lane A:0.5 mg Jurkat Whole Cell Lysate4 uL anti-MEF2D rabbit polyclonal antibody and 60 ug of Immunomagnetic beads Protein A/G.Primary antibody:Anti-MEF2D rabbit polyclonal antibody,at 1:100 dilutionSecondary antibody:Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilutionDeveloped using the ECL technique.Performed under reducing conditions.Predicted band size: 56 kDaObserved band size :70 kDa)

IF (Immunofluorescence)

(Immunofluorescence staining of MEF2D in U2OS cells. Cells were fixed with 4% PFA, permeabilzed with 0.1% Triton X-100 in PBS,blocked with 10% serum, and incubated with rabbit anti-Human MEF2D polyclonal antibody (dilution ratio 1:200) at 4 degree C overnight. Then cells were stained with the Alexa Fluor488-conjugated Goat Anti-rabbit IgG secondary antibody (green). Positive staining was localized to Nucleus.)

IHC (Immunohistochemisry)

(Immunochemical staining of human MEF2D in human placenta with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.)

IHC (Immunohiostchemistry)

(Immunochemical staining of human MEF2D in human skeletal muscle with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.)

WB (Western Blot)

(Anti-MEF2D rabbit polyclonal antibody at 1:500 dilutionLane A: HeLa Whole Cell LysateLane B: Jurkat Whole Cell LysateLane C: U-251 MG Whole Cell LysateLysates/proteins at 30 ug per lane.SecondaryGoat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution.Developed using the ECL technique.Performed under reducing conditions.Predicted band size:56 kDaObserved band size:65 kDa)

Related Product Information for anti-MEF2D antibody

MEF2D fusion genes are newly discovered recurrent genetic abnormalities that are detected in approximately 5% of acute lymphoblastic leukemia cases. Myocyte enhancer factor 2D (MEF2D), is a key survival protein and transcription factor. Loss of transcription factor myocyte enhancer factor 2D (MEF2D), a key neuronal survival factor, has been shown to underlie the loss of dopaminergic (DA) neurons in SNc and the pathogenic process of Parkinson's disease (PD). Both genetic factors and neurotoxins associated with PD impair MEF2D function in vitro and animal models of PD. It is known that PD-associated neurotoxins reduce the level of MEF2D protein to trigger neuronal death. The transcription factor MEF2D promotes the survival of various types of cells and functions as an oncogene in liver cancer. MEF2D is a candidate oncogene for osteosarcoma and a potential molecular target for cancer therapy.

Product Categories/Family for anti-MEF2D antibody

P38 MAPK Signaling Pathway

References

Yu H, et al. (2015) Mef2d overexpression contributes to the progression of osteosarcoma. Gene 563 (2): 130-135.Wang B, et al. (2014) Destabilization of survival factor mef2d mrna by neurotoxin in models of parkinson's disease. J Neurochem 130 (5): 720-728.Hirano D, et al. (2019) Chromosomal translocation-mediated evasion from mirna induces strong mef2d fusion protein expression, causing inhibition of pax5 transcriptional activity. Oncogene 38 (13): 2263-2274.Gao L, et al. (2014) Oxidation of survival factor mef2d in neuronal death and parkinson's disease. Antioxid Redox Signal 20 (18): 2936-2948.